Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 1, 2018

Quantification of vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid in urine using a dilute-and-shoot and ultra-high pressure liquid chromatography tandem mass spectrometry method

  • Eric Grouzmann EMAIL logo , Catherine Centeno and Philippe J. Eugster

Abstract

Background:

Urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) are biomarkers for the diagnosis and follow-up of neuroblastoma, whereas urinary 5-hydroxyindoleacetic acid (5-HIAA) is used to assess a carcinoid tumor. These analytes are conventionally analyzed in a single run by chromatography (LC) coupled with electrochemical detection (LC-ECD) using commercial kits. A rapid dilute-and-shoot LC tandem mass spectrometry (LC-MS/MS) assay was validated in order to replace the LC-ECD method and therefore improve analytical specificity and throughput.

Methods:

Sample preparation was carried out by dilution of the urine sample with a solution containing the deuterated internal standards. The separation was achieved on an ultra-high pressure LC system with MS detection using a triple quadrupole mass spectrometer. The method was validated according to the current EMA and FDA guidelines.

Results:

The full chromatographic run was achieved in 8 min. The method validation showed excellent linearity (r2>0.999 for all three analytes), precision (CV <15%), negligible matrix effect (recoveries >90%), low carryover (<1%) and LLOQ of 0.25, 0.4 and 0.4 μM for VMA, HVA and 5-HIAA, respectively. Deming fits and Bland-Altman analyses showed no significant differences between the values obtained between the two assays.

Conclusions:

The LC-MS/MS method proposed in this study is fast and robust, and the simple sample preparation saves time and avoids the additional costs of dedicated kits used for the LC-ECD assays by switching to LC-MS/MS. Additionally, the near-perfect correlation observed herein between both assays allows the previously established reference ranges to be maintained.


Corresponding author: Dr. Eric Grouzmann, Laboratoire des Catecholamines et Peptides, Service de Pharmacologie Clinique, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland, Phone: +41213140741, Fax: +41213147835

Acknowledgments

The authors thank Dr. Steve Bruce for the careful reading of the manuscript.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106–20.10.1038/npg.els.0006054Search in Google Scholar

2. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013;13:397–411.10.1038/nrc3526Search in Google Scholar

3. Pussard E, Neveux M, Guigueno N. Reference intervals for urinary catecholamines and metabolites from birth to adulthood. Clin Biochem 2009;42:536–9.10.1016/j.clinbiochem.2008.10.022Search in Google Scholar

4. Brodeur GM, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Am J Clin Oncol 1993;11:1466–77.10.1200/JCO.1993.11.8.1466Search in Google Scholar

5. Cangemi G, Barco S, Reggiardo G, Viscardi E, Di Cataldo A, Garaventa A, et al. Interchangeability between 24-hour collection and single spot urines for vanillylmandelic and homovanillic acid levels in the diagnosis of neuroblastoma. Pediatr Blood Cancer 2013;60:E170–2.10.1002/pbc.24671Search in Google Scholar

6. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047–53.10.1056/NEJMoa012277Search in Google Scholar

7. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858–68.10.1056/NEJM199903183401107Search in Google Scholar

8. O’Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O’Connor J, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 2009;90:194–202.10.1159/000225948Search in Google Scholar

9. Carling R, Degg T, Allen K, Bax N, Barth J. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem 2002;39:577–82.10.1177/000456320203900605Search in Google Scholar

10. Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. J Chromatogr B 2000;747:33–48.10.1016/S0378-4347(00)00341-8Search in Google Scholar

11. Williams CM, Greer M. Diagnosis of neuroblastoma by quantitative gas chromatographic analysis of urinary homovanillic and vanilmandelic acid. Clin Chim Acta 1962;7:880–3.10.1016/0009-8981(62)90076-1Search in Google Scholar

12. Muskiet FA, Fremouw-Ottevangers D, Nagel G, Wolthers B. Determination of 4-O-methylated catecholamine metabolites in urine by mass fragmentography. Clin Chem 1979;25:1708–13.10.1093/clinchem/25.10.1708Search in Google Scholar

13. Tran MT, Baglin J, Tran TT, Hoang KT, Phung LT, Read A, et al. Development of a new biochemical test to diagnose and monitor neuroblastoma in Vietnam: homovanillic and vanillylmandelic acid by gas chromatography-mass spectrometry. Clin Biochem 2014;47:206–15.10.1016/j.clinbiochem.2013.11.016Search in Google Scholar PubMed

14. Antonelli G, Marinova M, Artusi C, Plebani M. Mass spectrometry or immunoassay: est modus in rebus. Clin Chem Lab Med 2017;55:1243–5.10.1515/cclm-2017-0197Search in Google Scholar PubMed

15. Shen Y, Lu J, Tang Q, Guan Q, Sun Z, Li H, et al. Rapid, easy analysis of urinary vanillylmandelic acid for diagnostic testing of pheochromocytoma by liquid chromatography tandem mass spectrometry. J Chromatogr B 2015;1002:92–7.10.1016/j.jchromb.2015.08.013Search in Google Scholar PubMed

16. Clark ZD, Cutler JM, Pavlov IY, Strathmann FG, Frank EL. Simple dilute-and-shoot method for urinary vanillylmandelic acid and homovanillic acid by liquid chromatography tandem mass spectrometry. Clin Chim Acta 2017;468:201–8.10.1016/j.cca.2017.03.004Search in Google Scholar PubMed

17. Franscini LC, Vazquez-Montes M, Buclin T, Perera R, Dunand M, Grouzmann E, et al. Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: relevance to the diagnosis of neuroblastoma. Pediatr Blood Cancer 2015;62:587–93.10.1002/pbc.25385Search in Google Scholar PubMed

18. Hsu WY, Chen CM, Tsai FJ, Lai CC. Simultaneous detection of diagnostic biomarkers of alkaptonuria, ornithine carbamoyltransferase deficiency, and neuroblastoma disease by high-performance liquid chromatography/tandem mass spectrometry. Clin Chim Acta 2013;420:140–5.10.1016/j.cca.2012.10.022Search in Google Scholar PubMed

19. García-Valverde MT, Lucena R, Cárdenas S, Valcárcel M. Determination of urinary 5-hydroxyindoleacetic acid by combining Dμ-SPE using carbon coated TiO2 nanotubes and LC–MS/MS. Bioanalysis 2015;7:2857–67.10.4155/bio.15.205Search in Google Scholar PubMed

20. Moriarty M, Lee A, O’Connell B, Kelleher A, Keeley H, Furey A. Development of an LC-MS/MS method for the analysis of serotonin and related compounds in urine and the identification of a potential biomarker for attention deficit hyperactivity/hyperkinetic disorder. Anal Bioanal Chem 2011;401:2481–93.10.1007/s00216-011-5322-7Search in Google Scholar PubMed

21. Perry H, Keevil B. Online extraction of 5-hydroxyindole acetic acid from urine for analysis by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 2008;45:149–52.10.1258/acb.2007.007067Search in Google Scholar PubMed

22. Marcos J, Renau N, Valverde O, Aznar-Lain G, Gracia-Rubio I, Gonzalez-Sepulveda M, et al. Targeting tryptophan and tyrosine metabolism by liquid chromatography tandem mass spectrometry. J Chromatogr A 2016;1434:91–101.10.1016/j.chroma.2016.01.023Search in Google Scholar PubMed

23. Konieczna L, Roszkowska A, Niedzwiecki M, Baczek T. Hydrophilic interaction chromatography combined with dispersive liquid-liquid microextraction as a preconcentration tool for the simultaneous determination of the panel of underivatized neurotransmitters in human urine samples. J Chromatogr A 2016;1431:111–21.10.1016/j.chroma.2015.12.062Search in Google Scholar PubMed

24. Lionetto L, Lostia AM, Stigliano A, Cardelli P, Simmaco M. HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. Clin Chim Acta 2008;398:53–6.10.1016/j.cca.2008.08.003Search in Google Scholar PubMed

25. European Medicines Agency. Guideline on bioanalytical method validation. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf. Accessed: 2 Feb 2018.Search in Google Scholar

26. US Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. 2001. Available from: https://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf. Accessed: 2 Feb 2018.Search in Google Scholar

27. Corcuff JB, Chardon L, El Hajji Ridah I, Brossaud J. Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations. Endocr Connect 2017;6:R87–98.10.1530/EC-17-0071Search in Google Scholar PubMed PubMed Central

28. Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oosterhuis W, et al. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2015;53:833–5.10.1515/cclm-2015-0067Search in Google Scholar PubMed

29. Westgard QC. Within-subject and between-subject CV values of analytes and Desirable Analytical Quality Specifications for imprecision, bias and total error. Available from: https://www.westgard.com/biodatabase1.htm. Accessed: 9 Mar 2018.Search in Google Scholar


Supplementary Material:

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2017-1120).


Received: 2017-12-01
Accepted: 2018-03-27
Published Online: 2018-05-01
Published in Print: 2018-08-28

©2018 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2017-1120/pdf
Scroll to top button